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Genetic polymorphisms observed in various disease states associated with sensitivity or resistance to specific
treatments have been a robust area of investigation for decades, with the potential to allow clinicians to make
evidence-based decisions on the appropriate course of treatment. This study aimed to evaluate whether genetic
polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a
sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and
HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNα-RBV). We analyzed the associations between
SVR to PEG-IFNα-RBV therapy and 4 single nucleotide polymorphisms (SNPs) in STAT6. This study included
Taiwanese Chinese patients infected with either HCV-1 (n = 265) or HCV-2 (n = 195) in the presence or absence of
an SVR. Among the STAT6 SNPs examined, the dosage effect of the A allele and allele frequency in rs1059513 were
inversely correlated with SVR in patients infected with HCV-1 (P = 0.0179 and P = 0.0235, respectively). This effect
was not observed in patients infected with HCV-2. The GG, GGG, and GGGC STAT6 haplotypes comprising 2, 3, and
4 SNPs (rs1059513, rs703817, rs324015, and rs3024974) were found to be associated with SVR, and their presence
may increase the probability of a successful treatment outcome in patients infected with HCV-1 (P = 0.0273, 0.0352,
and 0.0368, respectively). Moreover, a multivariate logistic regression model for predicting an SVR revealed that the
presence of the GGGC haplotype carriers mutually affected the outcome of PEG-IFNα-RBV treatment. The presence
of STAT6 SNPs and the association with SVR demonstrated that STAT6 polymorphisms might influence the
therapeutic outcomes of patients infected with HCV-1 under standard-of-care (SOC) treatment.
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Hepatitis C is a common infectious disease caused by
hepatitis C virus (HCV). Infection with HCV is the
most common cause of chronic liver disease, hepa-
toma, and liver transplantation [1-3]. Typically, HCV
spreads through exposure to infected blood, especially
via intravenous drug abuse, which is a major route of
transmission. In addition to blood-borne exposure, HCV* Correspondence: d0704@mail.cmuh.org.tw; yihlin@asia.edu.tw;
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reproduction in any medium, provided the ormay also spread through sexual contact and vertical trans-
mission, albeit at lower risk [3]. It is estimated that ap-
proximately 170 million people worldwide are infected
with HCV [4,5].
The standard-of-care (SOC) treatment for chronic he-
patitis C includes a combination of pegylated interferon
alpha (PEG-IFNα) and ribavirin (RBV) [6,7]. The effec-
tiveness of 2 types of peginterferon, alfa-2a and alfa-2b,
both differing in their pharmacokinetic and chemical
properties, has been determined [8,9]. Peginterferon
alfa-2a plus ribavirin is more effective in treating chronic
hepatitis C than interferon alfa-2b plus ribavirin or
peginterferon alfa-2a alone [8]. In general, successful
treatment is defined as the persistent absence of serum. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as a sustained virological response (SVR) [10].
IFNα exert multifunctional biological activities and
consists of highly homologous proteins mediated by
binding to the receptor chains, IFNαR1 or IFNαR2 [11].
Binding of IFNα to its receptor leads to its activation
via two receptor-associated tyrosine kinases (Tyk2) and
Janus kinases 1 and 2 (JAK kinases 1 and 2), which
in turn triggers the activation of cytoplasmic factors,
namely, the STAT (signal transducers and activators of
transcription) family of proteins [11]. STAT6 is a cyto-
solic protein, the tyrosine phosphorylation of which is
catalyzed by JAK kinases 1 and 2 [11]. Subsequently,
phosphorylated STAT6 proteins dimerize via their SH2
domains and translocate into the nucleus, where they
bind to response elements of target genes and regulate
cytokine production [11,12]. STAT6 induces two forms
of cytokines, IL-4 and IL-13. Formation of STAT homo/
heterodimer in response to IFNα activation may initiate
transcription of several genes, including genes encoding
the transcription factor IFN regulatory factor 1 (IRF-1)
and IFN-stimulated gene factor 3 (ISGF3). The ISGF3
complex may trigger several subsets of genes termed
IFN-stimulated response elements (ISREs) by binding to
different parts of cis-acting elements [12]. The JAK/
STAT signaling pathway is activated when the cytokine
interleukins 4 (IL-4), IL-12, and/or type I interferon
(IFN) bind to their respective receptors. Since STAT6
protein is essential for responsiveness to IL-4 and IL-12,
STAT6-deficient mice do not produce significant num-
bers of type 2 CD4+ T cells, thereby blocking the differ-
entiation of these cells [13,14]. Furthermore, multiple
studies have demonstrated that STAT6 knockout mice
are resistant to tumor growth and spontaneous meta-
static disease [15]. Therefore, IFN-mediated activation
of STAT6 occurs via production of secreted IL-1Ra
during inflammatory responses [16]. STAT6 activation
has been reported to play an important role in the re-
gulation of genes responsible for their antitumor or
antiviral effects.
Previous studies have demonstrated that the SVR rates
for patients infected with HCV genotype 1 (HCV-1) are
significantly lower than the rates for those who are
infected with HCV genotype 2 (HCV-2). In order to val-
idate the potentially useful prognostic biomarkers that
are able to predict SVR during early treatment, previous
studies have used real-time PCR to estimate the expres-
sion profiles of 68 messenger RNAs isolated from HCV-
1 infected patients, as well as their correlation with SVR
[17]. Investigators found that STAT6 expression levels
are highly correlated with SVR. It has been suggested
that, in addition to inducing important molecular path-
ways, the expression of several early genes during HCV
therapy may also influence the capacity of residual SVR.In the present study, we investigated the association
between single nucleotide polymorphisms (SNPs) in the
STAT6 gene and their susceptibility to SVR in Chinese
patients in Taiwan receiving PEG-IFNα-RBV treatment.
Our results support the hypothesis that STAT6 is a po-
tential candidate gene for predicting therapeutic out-
comes of HCV-1 infected patients.
Methods
Patients
In the present study, 265 patients infected with HCV-1
and 195 patients infected with HCV-2 at the China
Medical University Hospital, Taichung, Taiwan were en-
rolled and actively observed. All participating subjects
provided informed consent, and the study protocol was
approved by the chairman of the Ethics Committee of
the China Medical University Hospital in accordance
with the guidelines of the Declaration of Helsinki. Diag-
nosis of HCV infection was based on persistent elevation
of serum transaminase levels for at least 6 months and
serum anti-HCV positivity, coupled with the periodic
detection of serum HCV RNA. Patients positive for
hepatitis B surface antigen, antibodies, and human im-
munodeficiency virus 1 and 2 were excluded in this
study. Patients received weekly injections of PEG-IFNα
(1.5 μg/kg body weight) plus body weight–adapted doses
of RBV (800 mg/day for < 60 kg; 1000 mg/day for
60–75 kg; 1200 mg/day for > 75 kg) by oral adminis-
tration for 48 weeks (HCV-1) or 24 weeks (HCV-2).
SNP selection
Selection of representative STAT6 SNPs was based on
SNP genotype information, downloaded in December
2008 from the HapMap Chinese Han in Beijing (CHB) +
JPT population. HapMap genotypes were further ana-
lyzed via Haploview software (version 4.2; Broad Insti-
tute, Cambridge, MA, USA). Tag SNPs were selected by
using the Tagger function according to the following cri-
teria: (1) a minor allele frequency (MAF) in the HapMap
CHB + JPT population of > 0.10; and (2) a genotyping
score of ≥ 0.6 (Illumina, Inc., San Diego, CA), as re-
commended by the manufacturer, to achieve a successful
genotyping rate. Four SNPs in the STAT6 gene met the
above criteria and were selected, including rs1059513
(S1; A/G at 3′ UTR), rs703817 (S2; A/G at 3′ UTR),
rs324015 (S3; A/G at 3′ UTR), and rs3024974 (S4; C/T
at boundary of intron 17).
HCV genotyping and RNA measurements
Genotyping of HCV according to the classification of
Simmonds et al. [18] was performed by a reverse hy-
bridization assay (INNO LiPA HCV-II; Innogenetics,
Ghent, Belgium). The virological response was assessed
by qualitative HCV RNA assays with a lower sensitivity
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nostics, Branchburg, NJ, USA). According to the qualita-
tive HCV RNA results (reported in copies/mL), patients
were defined as (1) sustained virological responders
(HCV RNA undetectable at week 24 posttreatment) and
(2) non-sustained virological responder (HCV RNA de-
tected at week 24 posttreatment). Thus, the subjects were
classified as either SVR (+) or SVR (−), respectively.
Genomic DNA extraction and genotyping
Genomic DNA was isolated from the peripheral blood
of all participants by using a commercial kit (Genomic
DNA kit; QIAGEN, Valencia, CA, USA) according to the
manufacturer’s instructions. Four STAT6 polymorphisms
were detected by an allele-specific extension method and
ligation assay kit (Illumina, San Diego, CA, USA), in ac-
cordance with the manufacturer’s instructions.
Statistical analysis
Gender, age, body mass index (BMI), and viral load dif-
ferences between SVR (+) and SVR (−) groups were esti-
mated using the Mann–Whitney U test. The differences
between genotypes and each of the above mentioned pa-
rameters were estimated using the Kruskal–Wallis test.
The association of each SNP with SVR was assessed
using the chi-square (χ2) test or Fisher’s exact test. Ge-
notype and allele frequencies in SVR (+) and SVR (−)
patients were compared, and odds ratios (ORs) with a
95% confidence interval (CI) were estimated by applying
an unconditional logistic regression model. Haplotype
analysis using a sliding window mode and Hardy–
Weinberg equilibrium (HWE) analysis were performed
using the PLINK program (version 1.07; http://pngu.
mgh.harvard.edu/purcell/plink/) [19]. The distributionTable 1 Characteristics of the HCV genotype 1 and 2 infected
HCV genotype 1 (HCV-1)
All SVR (+) SVR (−)
Number of patients 265 163 102
Gender (males/females) 129/136 84/79 45/57
Age (mean ± SD) 52.17 ± 10.27 50.69 ± 10.60 54.52 ± 9.2




Stage of fibrosis (F0/F1-4)c 16/249 6/157 10/92
AST (U/L) (mean ± SD) 76.15 ± 41.24 90.91 ± 61
ALT (U/L) (mean ± SD) 118.56 ± 75.99 108.05 ± 7
Platelet (× 103/μl) (mean ± SD) 176.4 ± 56.7 154.9 ± 59
Viral load (× 106) 12.1 ± 16.4 11.0 ± 16.5 13.9 ± 16.2
Abbreviations: SVR sustained virological response, BMI body mass index.
a Calculated by Mann–Whitney U test.
b Calculated by the χ2 test.
c The inflammatory activity and the stage of fibrosis were graded according to theof each haplotype frequency was identified using Phase
version 2.1 (University of Chicago, Chicago, IL, USA),
a computational tool based on Bayesian methods [20].
Multivariate logistic regression analysis was used to pre-
dict the independent variables that correlated with a the-
rapeutic response. An OR at a 95% CI was employed for
this analysis. Statistical tests were performed using SPSS
software (version 20.0 for Windows; SPSS Inc., Chicago,
IL, USA). Statistical significance was defined as P < 0.05
and was two-sided. Screening and construction of linkage
disequilibrium (LD) plots were performed using Haplo-
view software (version 4.2).
Results
Patient characteristics
In this study, 460 patients infected with HCV-1 (n = 265)
and HCV-2 (n = 195) were successfully enrolled. Patients
infected with HCV-2 achieved SVR at higher rates than
patients infected with HCV-1 (91.3% vs. 61.5%). The basic
characteristics and clinical information of all patients
infected with HCV-1 and HCV-2 are displayed in Table 1.
The information is further stratified by HCV genotype.
We observed several significant differences between SVR
(+) and SVR (−) groups, including their age (starting with
date of entry), body mass index (BMI), platelets and viral
load in HCV-1–infected patients (P = 0.002, P = 0.026,
P = 0.002, and P = 0.001, respectively). Some effects were
not observed significantly in HCV-2 infected populations.
However, statistically significant differences in the afore-
mentioned variables were not observed among the 4
SNPs.
The chromosome position, Hardy–Weinberg equilib-
rium (HWE), and MAF in individuals bearing the afore-
mentioned 4 STAT6 SNPs genotypes examined in thispatients receiving PEG-IFNα-RBV therapy
HCV genotype 2 (HCV-2)
P value All SVR (+) SVR (−) P value
- 195 178 17 -
0.241 88/107 81/97 7/10 0.732
9 0.002a 51.62 ± 10.89 51.15 ± 11.16 56.47 ± 5.86 0.050a
0.026a 24.5 ± 3.5 24.5 ± 3.6 24.5 ± 2.7 0.863a
0.0913b 22/173 18/160 4/13 0.0948b
0.0417b 10/185 7/171 3/14 0.0143b
.12 0.049a 84.26 ± 63.45 78.12 ± 34.03 0.744a
4.97 0.328a 120.67 ± 104.63 100.71 ± 44.76 0.822a
.5 0.002a 174.4 ± 52.4 125.5 ± 41.8 0.001a
0.001a 11.0 ± 19.0 10.3 ± 17.8 18.4 ± 27.9 0.334a
Metavir scoring system [21].
Table 2 Four single nucleotide polymorphisms in the STAT6 gene in 265 HCV-1 and 195 HCV-2 infected patients













SVR (+) SVR (−) SVR (+) SVR (−)
rs1059513 (S1) 3′ UTR 57489709 A/G 0.3808 0.0982 0.0441 1 0.0646 0.0589
rs703817 (S2) 3′ UTR 57489828 A/G 0.7565 0.2454 0.3119 0.7054 0.2612 0.1471
rs324015 (S3) 3′ UTR 57490100 A/G 0.5347 0.4448 0.4406 0.5655 0.4831 0.4118
rs3024974 (S4) Intron 17
(boundary)
57492745 C/T 0.8524 0.2086 0.2108 0.6503 0.1949 0.2059
Abbreviations: SNP single nucleotide polymorphism, HWE Hardy-Weinberg equilibrium, MAF minor allele frequency.
a Chromosome positions refer to the sequence in the NCBI database (built 37.3).
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dance with HWE (P > 0.05).
Association of tagging SNPs of STAT6 with therapeutic
response and SVR
The genotype frequencies and allelic dose-dependent
association of each SNP with responsiveness to PEG-
IFNα-RBV therapy are displayed in Table 3. In genotypeTable 3 Genotype frequencies of STAT6 single nucleotide pol
receiving PEG-IFNα-RBV therapy with and without a SVR in a
HCV-1
SNP ID SVR (+) SVR (−) P OR (95% CI)
N (%) N (%)
rs1059513
A/A 131 (80.4) 93 (91.2) 0.40 (0.18, 0.87)
A/G 32 (19.6) 9 (8.8) 0.0179* 1
G/G 0 (0.0) 0 (0.0) - -
A/A + A/G 163 (100.0) 102 (100.0) - -
rs703817a
A/A 11 (6.7) 9 (8.9) 0.61 (0.24, 1.58)
A/G 58 (35.6) 45 (44.6) 0.64 (0.38, 1.09)
G/G 94 (57.7) 47 (46.5) 0.2103 1
A/A + A/G 69 (42.3) 54 (53.5) 0.0780 0.64 (0.39, 1.05)
rs324015a
A/A 34 (20.9) 20 (19.8) 1.05 (0.52, 2.12)
A/G 77 (47.2) 49 (48.5) 0.97 (0.55, 1.71)
G/G 52 (31.9) 32 (31.7) 0.9723 1
A/A + A/G 111 (68.1) 69 (68.3) 0.9704 0.99 (0.58, 1.69)
rs3024974
C/C 105 (64.4) 61 (59.8) 0.34 (0.07, 1.62)
C/T 48 (29.5) 39 (38.2) 0.25 (0.05, 1.19)
T/T 10 (6.1) 2 (2.0) 0.1285 1
C/C + C/T 153 (93.9) 100 (98.0) 0.1118 0.31 (0.07, 1.43)
a Contains 1 missing data point in the SVR (−) group.
b Contains 1 missing data point in the SVR (+) group.
Abbreviations: SNP single nucleotide polymorphism, SVR sustained virological respo
Genotype frequencies were determined by χ2 test using 2 × 3 or 2 × 2 tables as ap
unconditional logistic regression. P values less than 0.05 were considered statisticalassociation tests, only genotypes from rs1059513 were
significantly associated with SVR in HCV-1 infected
patients (P = 0.0179). When the A/A and A/G geno-
types were compared, a decreased crude OR of 0.40
(95% CI, 0.18–0.87; P = 0.0179) for SVR (+) versus SVR
(−) groups was observed. However, no genotype was sig-
nificantly associated with SVR in the HCV-2 infected
population.ymorphisms (SNPs) in HCV-1 and HCV-2 infected patients
Chinese population in Taiwan
HCV-2
SNP ID SVR (+) SVR (−) P OR (95% CI)
N (%) N (%)
rs1059513
A/A 155 (87.1) 15 (88.2) 0.90 (0.19, 4.19)
A/G 23 (12.9) 2 (11.8) 0.8916 1
G/G 0 (0.0) 0 (0.0) - -
A/A + A/G 178 (100.0) 17 (100.0) - -
rs703817
A/A 11 (6.2) 0 (0.0) -
A/G 71 (39.9) 5 (29.4) 1.78 (0.60, 5.27)
G/G 96 (53.9) 12 (70.6) 0.3223 1
A/A + A/G 82 (46.1) 5 (29.4) 0.1869 2.05 (0.69, 6.06)
rs324015
A/A 39 (21.9) 6 (35.3) 0.43 (0.10, 1.85)
A/G 94 (52.8) 8 (47.1) 0.78 (0.20, 3.09)
G/G 45 (25.3) 3 (17.6) 0.4339 1
A/A + A/G 133 (74.7) 14 (82.4) 0.4851 0.63 (0.17, 2.31)
rs3024974b
C/C 113 (63.9) 11 (64.7) 2.05 (0.22, 19.19)
C/T 59 (33.3) 5 (29.4) 2.36 (0.23, 24.33)
T/T 5 (2.8) 1 (5.9) 0.7623 1
C/C + C/T 172 (97.2) 16 (94.1) 0.4867 2.15 (0.24, 19.55)
nse, OR odds ratio, CI Confidence interval.
propriate. Odds ratios and 95% CI per genotype were estimated by
ly significant, and are denoted with an asterisk.
Table 4 Allele frequencies of STAT6 single nucleotide polymorphisms in HCV-1 and HCV-2 infected patients receiving




SVR (+) SVR (−) P OR (95% CI) SNP
ID
SVR (+) SVR (−) P OR (95% CI)
N (%) N (%) N (%) N (%)
rs1059513 rs1059513
A allele 294 (90.2) 195 (95.6) 0.42 (0.20, 0.91) A allele 333 (93.5) 32 (94.1) 0.90 (0.20, 4.01)
G allele 32 (9.8) 9 (4.4) 0.0235* 1 G allele 23 (6.5) 2 (5.9) 0.8954 1
rs703817a rs703817
A allele 80 (24.5) 63 (31.2) 0.72 (0.49, 1.06) A allele 93 (26.1) 5 (14.7) 2.05 (0.77, 5.45)
G allele 246 (75.5) 139 (68.8) 0.0948 1 G allele 263 (73.9) 29 (85.3) 0.1425 1
rs324015a rs324015
A allele 145 (44.5) 89 (44.1) 1.02 (0.71, 1.45) A allele 172 (48.3) 20 (58.8) 0.65 (0.32, 1.34)
G allele 181 (55.5) 113 (55.9) 0.9249 1 G allele 184 (51.7) 14 (41.2) 0.2416 1
rs3024974 rs3024974b
C allele 258 (79.1) 161 (78.9) 1.01 (0.66, 1.56) C allele 285 (80.5) 27 (79.4) 1.07 (0.45, 2.56)
T allele 68 (20.9) 43 (21.1) 0.9518 1 T allele 69 (19.5) 7 (20.6) 0.8777 1
a Contains 1 missing data point in the SVR (−) group.
b Contains 1 missing data point in the SVR (+) group.
Abbreviations: SNP single nucleotide polymorphism, SVR sustained virological response, OR odds ratio, CI confidence interval.
Allele frequencies were determined by χ2 test using 2 × 2 tables. Odds ratios and 95% CI per allele were estimated by unconditional logistic regression. P values
less than 0.05 were considered statistically significant, and are denoted with an asterisk.
Table 5 Details of sex-adjusted haplotype frequency
analysis for 2-SNP, 3-SNP, and 4-SNP windows showing
the most significant results among all possible sliding
windows in HCV-1 infected patients
Haplotypes SVR (+) SVR (−) OR P value
rs1059513-rs703817 (S1-S2)
OMNIBUS - - - 0.0401*
GG (22) 0.0982 0.0450 2.31 0.0273*
rs1059513-rs703817-rs324015 (S1-S2-S3)
OMNIBUS - - - 0.1101
GGG (222) 0.0948 0.0447 2.24 0.0352*
rs1059513-rs703817-rs324015-rs3024974 (S1-S2-S3-S4)
OMNIBUS - - - 0.1894
GGGC (2221) 0.0960 0.0457 2.22 0.0368*
Abbreviations: SVR sustained virological response, OR odds ratio.
P values less than 0.05 were considered statistically significant, and are
denoted with an asterisk.
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SNPs allele frequencies between SVR (+) and SVR (−)
groups in patients infected with HCV-1 and HCV-2 are
displayed in Table 4. Compared with SVR (+) individ-
uals, patients harboring the A allele of SNP rs1059513
were at an increased risk for non-responsiveness to SOC
treatment (P = 0.0235; OR = 0.42, 95% CI, 0.20–0.91),
with a significance observed exclusively in patients in-
fected with HCV-1. Thus, HCV-1 infected individuals
with STAT6 rs1059513 A/A genotype and carrying the A
allele may be at increased risk for non-responsiveness to
PEG-IFNα-RBV treatment.
Frequencies of the STAT6 haplotypes and the association
with SVR
We performed a comparative analysis of haplotype fre-
quencies and treatment responses by adjustment for
gender as a covariate by using the PLINK program. The
results of the overall global test and haplotype frequen-
cies are displayed in Table 5. The analysis was introduced
by the sliding window mode to examine the potential sizes
of all haplotypes (number SNPs per haplotype). As a re-
sult, there were 10 sliding windows, 1 of which (the omni-
bus test) was significantly associated with SVR in HCV-1
infected patients (P < 0.05).
In HCV-1 infected populations possessing haplotype
GG, the window S1-S2 (composed of rs1059513 and
rs703817), gave the most significant P value (P = 0.0273;
OR = 2.31). Haplotype-specific analyses showed that the
GGG haplotype (S1-S2-S3, composed of rs1059513,rs703817, and rs324015) may increase the rate of SVR
(P = 0.0352; OR = 2.24) in the SVR (+) groups compared
with the SVR (−) groups. The window S1-S2-S3-S4
with the GGGC haplotype (composed of rs1059513,
rs703817, rs324015, and rs3024974) was significantly as-
sociated with a higher rate of SVR in HCV-1 infected
patients (OR = 2.22; P = 0.0368). Furthermore, the results
demonstrated that HCV-1 infected patients with thera-
peutic response bearing the haplotypes GG, GGG, and
GGGC, appeared more frequently in SVR (+) groups
than in SVR (−) groups. However, the haplotypes did not
Table 6 Distribution of haplotype frequencies from SNPs of STAT6 gene in 265 HCV-1 infected populations and their
associations with SVR
Haplotypes* SVR (+) (%) SVR (−) (%) P Global† P individual§ OR (95% CI)
AGGT 66 (20.3) 40 (19.6) 0.2126 0.8583 1.04 (0.67, 1.61)
AGGC 4 (1.2) 2 (1.0) 0.7940 1.25 (0.23, 6.91)
AGAT 2 (0.6) 3 (1.5) 0.3206 0.41 (0.07, 2.50)
AGAC 144 (44.2) 87 (42.6) 0.7305 1.06 (0.75, 1.51)
AAGC 78 (23.9) 63 (30.9) 0.0778 0.70 (0.48, 1.04)
GGGC 31 (9.5) 9 (4.4) 0.0306* 2.28 (1.06, 4.89)
GGAC 1 (0.3) 0 (0.0) 0.4285 -
*Order of SNPs comprising the STAT6 haplotypes: rs1059513, rs703817, rs324015 and rs3024974. The haplotypes were identified by the Bayesian statistical method
available in the program Phase 2.1.
† Global test for haplotypes frequency in relation to SVR was determined by χ2 test using 2 × 7 contingency tables.
§ Individual haplotype frequency in relation to SVR was determined by χ2 test using 2 × 2 contingency tables. P values less than 0.05 were considered statistically
significant, and are denoted with an asterisk. ORs and 95% CI were estimated by unconditional logistic regression model.
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not shown). Thus, in the HCV-1 infected individuals,
haplotype-specific analyses showed that the aforemen-
tioned haplotypes are associated with an increase success
rate of SVR and may play a role in the therapeutic out-
comes of PEG-IFNα-RBV treatment in HCV-1 infected
patients. Table 6 shows that 9.5% of 163 SVR (+) HCV-1
infected patients possessed the GGGC haplotype. The
GGGC haplotype carriers achieved a significantly higher
SVR rate compared with non-GGGC carriers (95% CI,
1.06–4.89, OR = 2.28; P = 0.0306). These findings con-
firmed the results of our analyses of genotypes, allele fre-
quencies, and haplotypes.
We performed LD analysis, and the results were viewed
using Haploview software (version 4.2). Our results indi-
cated that a low degree of pairwise LD among these SNPs
in all HCV-1 infected populations in the presence orFigure 1 Linkage disequilibrium plot of the STAT6 gene for the analy
linkage disequilibrium plot where each square (with r2 values written withi
measure range) represents a pairwise linkage disequilibrium relationship be
disequilibrium (r2 = 1); mid colored squares indicate r2 values between 0 an
(r2 = 0). Figure depicts the linkage disequilibrium pattern in (A) all HCV-1 in
patients; (C) HCV-1 infected PEG-IFNα-RBV therapy with SVR (−) patients.absence of SVR. The graphical summary of LD (r2 values)
among tested 4 STAT6 SNPs at different loci is displayed
in Figure 1. Four tag SNPs were selected and designated
in sequential order.
Multivariate logistic regression analysis
We subsequently determined whether independent fac-
tors affected the outcome of PEG-IFNα-RBV therapy.
To this end, we performed multivariate logistic regres-
sion analyses with respect to GGGC/non-GGGC haplo-
types, age, BMI, and HCV RNA levels (low/high). This
analysis revealed that the GGGC haplotype carrier acts
as an independent predictor of the virological response
outcome of PEG-IFNα-RBV therapy (P = 0.043; OR = 2.32,
95% CI, 1.03–5.23) (Table 7). Furthermore, age and HCV
viral load may also act together to influence the out-
come of PEG-IFNα-RBV treatment (P = 0.012; OR = 0.97,zed SNPs. The figure shows the output of Haploview (version 4.2)
n the box correspond to r2 values × 100 as linkage disequilibrium
tween the two SNPs. Darkest colored squares indicate high linkage
d 1; lightest colored squares indicate low linkage disequilibrium
fected patients; (B) HCV-1 infected PEG-IFNα-RBV therapy with SVR (+)
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Discussion
The present study examined the genetic association of
HCV infection under PEG-IFNα-RBV therapy on a re-
sponsive gene, STAT6, and responsiveness of treatment.
We confirmed that this gene, located on chromosome
12, is a novel candidate susceptibility gene. The results
showed that rs1059513 at the 3′ UTR of STAT6 may be
associated with SVR rates under SOC treatment. The-
rapeutic outcome association studies showed that the
presence of the GGGC haplotype was significantly as-
sociated with a higher rate of SVR (OR = 1.06–4.89) in
HCV-1 infected but not HCV-2 infected populations. By
using multivariate logistic regression analyses, we ob-
served that the GGGC haplotype, age of entry, and viral
load may act interactively to influence the therapeutic
outcomes. This result suggests that the SVR rates of
PEG-IFNα-RBV treatment could, at least partially, de-
pend on STAT6 activation.
Thus far, the standard treatment regimen for chronic
hepatitis C infection has been a combination of PEG-
IFNα and RBV [8]. About 50% of treatment-naïve popu-
lations will typically achieve SVR by using this regimen
[8]. The SVR rate is markedly higher in HCV-2/3 infec-
ted patients than in HCV-1 infected patients (~ 85% ver-
sus 40%) [8]. In order to identify the biomarkers that
distinguish the profiles of HCV therapeutic responsive-
ness, Younossi and colleagues [17] collected RNA trans-
cripts from peripheral blood mononuclear cells (PBMCs)
of 68 HCV-infected patients under PEG-IFNα-RBV treat-
ment. After preparing expression profiles of patients
under this treatment, the investigators observed that gen-
etic expression of STAT6 and cytokine signaling 1 are pu-
tative predictive markers that correlate with SVR [17]. In
support of this finding, we also observed a correlation be-
tween STAT6 genetic polymorphisms and SVR.Table 7 Predictive factors associated independently with
the SVR to PEG-IFNα-RBV therapy in HCV-1 infected
populations by multivariate logistic regression analysis
Parameter P value OR (95% CI)
Haplotype§ (GGGC/non-GGGC) 0.043* 2.32 (1.03, 5.23)
Age 0.012* 0.97 (0.94, 1.00)
BMI 0.060 0.92 (0.85, 1.00)
HCV-RNA levelδ (low/high) 0.050* 8.11 (0.98, 67.32)
Abbreviation: CI confidence interval, BMI body mass index.
§ The order of the SNPs comprising the STAT6 haplotype was rs1059513,
rs703817, rs324015, and rs3024974.
δ Low HCV-RNA level: <100 KIU/ml by Amplicore-monitor assay. Odds ratios
(OR) of having a SVR to PEG-IFNα-RBV therapy were calculated. P values less
than 0.05 were considered statistically significant, and are denoted with
an asterisk.During viral infections, innate immunity remains the
most important first line of defense in the body. Viral
nucleic acids are detected by endosomal Toll-like re-
ceptors (TLRs) and cytoplasmic RIG-I–like receptors
(RLRs), which subsequently induce the production of
type 1 IFN to inhibit viral replication [22]. Consequently,
many cytokines (including type 1 IFNs) trigger the IFN-
stimulated gene expression cascade through the ca-
nonical JAK-STAT signaling pathway [23]. Previous
studies have shown that STAT6 activation is ubiqui-
tously detected during viral infections, concluding that
STAT6 may play a fundamental role in the defense
mechanism against viral infections [24]. Viral load,
age of entry into the study, and BMI were not signifi-
cantly different among the STAT6 genotypes of our
enrolled populations. Thus, it is unlikely that specific
STAT6 genotypes predispose individuals to infection
with HCV or contribute to the process of spontaneous
viral elimination.
Studies using a microarray platform to examine the
differential gene expression profiles of IL-4–stimulated B
cells between wild-type and Stat6−/− mice were recently
performed [25]. Seventy known genes were found to be
differentially expressed with significant discrepancies be-
tween the 2 mouse groups, which were all negatively or
positively regulated by STAT6 via a palindromic consen-
sus sequence TTC(N)2-4GAA [26]. In addition, STAT6
remains a critical determinant in the polarization and dif-
ferentiation process of T-helper type 2 (Th2) cells in a
Stat6 knockout mouse model [27]. The expression levels
of Th2-related cytokines (including IL-4, IL-5, and IL-13)
were diminished in this mouse model [27]. Moreover,
STAT6 may trigger a Th1 response by enhancing the
production of IL-12 through the inhibition of IL-10 pro-
duction in dendritic cells [28]. Therefore, STAT6 is also a
critical factor in the homeostasis of inflammatory and
hypersensitivity immune responses other than those
associated with viral immunity.
Several reports have provided strong evidence that pa-
tients infected with HCV-1 will have approximately a
50% probability (in Caucasians) or 80% probability (in
African Americans) of a poor response toward PEG-
IFNα-RBV treatment [8]. Although viral clearance rates
have been strongly associated with clinical features of
HCV, for example: gender, age < 40 years, low HCV
RNA levels pre-treatment, in the absence of liver cirrho-
sis, and HCV genotypes 2/3 [29]. Table 7 lists 11 pa-
tients with low viremia. Fried et al. [8] concluded that
HCV RNA level is one of the main factors affecting
treatment outcome; therefore, we performed multiva-
riate analysis to check whether HCV RNA level is an
independent factor of treatment outcome. We first de-
termined the HCV RNA baseline without categorizing
the patients; however, in this analysis, P = 0.182 and
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the best model for prediction of treatment outcome.
Therefore, we categorized the HCV RNA level according
to the description of Fujimoto et al. [30], with low HCV
RNA level <100 KIU/ml by Amplicore-monitor assay
and performed statistical analysis, and the results for this
analysis are more obviously (P = 0.050, OR = 8.11).
Many investigators continue to monitor the host gen-
etic factors that may relate to clinical outcomes to pro-
vide custom-made therapy for HCV infection. In our
study, the overall achievement response rates of SVR
were less than 62% and 92% in the HCV-1 and HCV-2
populations, respectively. Thus, a reliable prediction of a
subject as a potential non-viral responder (NVR) at the
start of treatment would allow the clinician to make ap-
propriate, evidence-based decisions on the compatibility
of future treatment, thereby reducing side effects and/or
the cost of treatment.
The contributions of host genetic factors to HCV-2/3
clearance are relatively small compared with HCV-1
clearance, because the former is more likely to be elimi-
nated by SOC therapy [8]. In the present study, we ob-
served an association between the STAT6 haplotype
GGGC and the rate of SVR, although its statistical sig-
nificance in the HCV-1 infected populations based on
estimation by multivariate logistic regression was mar-
ginal. The frequency of the GGGC allele in our popula-
tion was small, whether the frequency of this haplotype
is significant in other ethnic groups remains unknown.
We propose that this STAT6 haplotype GGGC might
play a role in the outcome of PEG-IFNα-RBV therapy
(adjusted r2 = 11.2%). The linkage among the STAT6
polymorphisms and SVR should be confirmed in future
studies with larger sample sizes. Moreover, the signifi-
cance of the genetic effects of STAT6 on other racial and
ethnic groups remains to be elucidated.
The mechanisms of action of the aforementioned 4
SNPs located within the 3′ UTR and intronic regions
of STAT6 gene are hampered by the lack of published
functional studies on these polymorphisms and war-
rants further investigation at the molecular level.Conclusion
This study provides evidence that the STAT6 genetic
polymorphisms are related to the susceptibility of HCV-
infected patients, especially HCV-1 infected patients to
SVR. Furthermore, an outcome measure of haplotype
GGGC in the clinical response was identified. Thus,
STAT6 may play an important role in a broad range of
antiviral activities under PEG-IFNα-RBV treatment.Competing interests
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